Chitosan-Based Nanoparticles

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Biomaterials of Marine Origin".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 5788

Special Issue Editors

Orthopedic Research Center, School of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
Interests: cancer biology; regenerative medicine; nano-medicine; drug delivery
Special Issues, Collections and Topics in MDPI journals
Institute of Food Science, Pukyong National University, Busan 48513, Korea
Interests: cancer biology; diabetes; wound healing; regenerative medicine; translation medicine; polymeric nanoparticles; drug delivery system

Special Issue Information

Dear Colleagues,

In the recent past, the biomedical research community has experienced unlimited benefit from nano-based therapeutic materials. In particular, chitosan-based nanomaterials have gained a great deal of attention in various fields, including the food, pharmaceutical, biomedical and environmental industries, owing to its safe profile, biocompatibility, and biodegradability nature. The uniqueness of its shape, size, and physiochemical features may augment the beneficial pharmacological activities. A series of recent studies have proven that chitosan is amongst the most studied and researched biomaterials. Therefore, this Special Issue will unite researchers, translational scientists, and physicians to address all the aspects of marine-derived chitosan-based nanomaterials, beyond the structural, functional, therapeutic and biomedical applications. We also welcome critical reviews from the experts in these subjects. All submissions should be related to marine-derived chitosan.

I'm looking forward to hearing from you soon.

Dr. Mariadoss Arokia Vijaya Anand
Dr. Surendhiran Duraiarasan
Dr. Cédric Delattre
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chitosan nanomaterial/nanocomposites
  • self-assembled chitosan nanoparticles
  • nanoparticles for cancer therapy, metabolic disorders and wound healing
  • chitosan nanoparticles used in tissue engineering
  • nano-based drug and vaccine delivery system
  • antimicrobial food packaging applications
  • eco-safety of chitosan nanoparticles

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 5312 KiB  
Article
Preparation and Characterization of Salsalate-Loaded Chitosan Nanoparticles: In Vitro Release and Antibacterial and Antibiofilm Activity
by Sivarasan Ganesan, Jagadeesh Kumar Alagarasan, Mohandoss Sonaimuthu, Kanakaraj Aruchamy, Fatemah Homoud Alkallas, Amira Ben Gouider Trabelsi, Fedor Vasilievich Kusmartsev, Veerababu Polisetti, Moonyong Lee and Huang-Mu Lo
Mar. Drugs 2022, 20(12), 733; https://0-doi-org.brum.beds.ac.uk/10.3390/md20120733 - 24 Nov 2022
Cited by 5 | Viewed by 1692
Abstract
The controlled-release characteristic of drug delivery systems is utilized to increase the residence time of therapeutic agents in the human body. This study aimed to formulate and characterize salsalate (SSL)-loaded chitosan nanoparticles (CSNPs) prepared using the ionic gelation method and to assess their [...] Read more.
The controlled-release characteristic of drug delivery systems is utilized to increase the residence time of therapeutic agents in the human body. This study aimed to formulate and characterize salsalate (SSL)-loaded chitosan nanoparticles (CSNPs) prepared using the ionic gelation method and to assess their in vitro release and antibacterial and antibiofilm activities. The optimized CSNPs and CSNP–SSL formulation were characterized for particle size (156.4 ± 12.7 nm and 132.8 ± 17.4 nm), polydispersity index (0.489 ± 0.011 and 0.236 ± 132 0.021), zeta potential (68 ± 16 mV and 37 ± 11 mV), and entrapment efficiency (68.9 ± 2.14%). Physicochemical features of these nanoparticles were characterized using UV–visible and Fourier transform infrared spectroscopy and X-ray diffraction pattern. Scanning electron microscopy studies indicated that CSNPs and CSNP–SSL were spherical in shape with a smooth surface and their particle size ranged between 200 and 500 nm. In vitro release profiles of the optimized formulations showed an initial burst followed by slow and sustained drug release after 18 h (64.2 ± 3.2%) and 48 h (84.6 ± 4.23%), respectively. Additionally, the CSNPs and CSNP–SSL nanoparticles showed a sustained antibacterial action against Staphylococcus aureus (15.7 ± 0.1 and 19.1 ± 1.2 mm) and Escherichia coli (17.5 ± 0.8 and 21.6 ± 1.7 243 mm). Interestingly, CSNP–SSL showed better capability (89.4 ± 1.2% and 95.8 ± 0.7%) than did CSNPs in inhibiting antibiofilm production by Enterobacter tabaci (E2) and Klebsiella quasipneumoniae (SC3). Therefore, CSNPs are a promising dosage form for sustained drug delivery and enhanced antibacterial and antibiofilm activity of SSL; these results could be translated into increased patient compliance. Full article
(This article belongs to the Special Issue Chitosan-Based Nanoparticles)
Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1398 KiB  
Review
Chitosan Nanoparticles-Based Cancer Drug Delivery: Application and Challenges
by Bhuvi Sachdeva, Punya Sachdeva, Arvind Negi, Shampa Ghosh, Sungsoo Han, Saikat Dewanjee, Saurabh Kumar Jha, Rakesh Bhaskar, Jitendra Kumar Sinha, Ana Cláudia Paiva-Santos, Niraj Kumar Jha and Kavindra Kumar Kesari
Mar. Drugs 2023, 21(4), 211; https://0-doi-org.brum.beds.ac.uk/10.3390/md21040211 - 28 Mar 2023
Cited by 13 | Viewed by 3040
Abstract
Chitin is the second most abundant biopolymer consisting of N-acetylglucosamine units and is primarily derived from the shells of marine crustaceans and the cell walls of organisms (such as bacteria, fungi, and algae). Being a biopolymer, its materialistic properties, such as biodegradability, [...] Read more.
Chitin is the second most abundant biopolymer consisting of N-acetylglucosamine units and is primarily derived from the shells of marine crustaceans and the cell walls of organisms (such as bacteria, fungi, and algae). Being a biopolymer, its materialistic properties, such as biodegradability, and biocompatibility, make it a suitable choice for biomedical applications. Similarly, its deacetylated derivative, chitosan, exhibits similar biocompatibility and biodegradability properties, making it a suitable support material for biomedical applications. Furthermore, it has intrinsic material properties such as antioxidant, antibacterial, and antitumor. Population studies have projected nearly 12 million cancer patients across the globe, where most will be suffering from solid tumors. One of the shortcomings of potent anticancer drugs is finding a suitable cellular delivery material or system. Therefore, identifying new drug carriers to achieve effective anticancer therapy is becoming essential. This paper focuses on the strategies implemented using chitin and chitosan biopolymers in drug delivery for cancer treatment. Full article
(This article belongs to the Special Issue Chitosan-Based Nanoparticles)
Show Figures

Figure 1

Back to TopTop